VB 1300
Alternative Names: VB-1300Latest Information Update: 14 Dec 2023
At a glance
- Originator VectivBio
- Developer Ironwood Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Lipid metabolism disorders
Most Recent Events
- 12 Dec 2023 VectivBio has been acquired and merged into Ironwood Pharmaceuticals
- 03 Feb 2022 Early research in Lipid metabolism disorders in Switzerland (unspecified route) (VectivBio pipeline, February 2022)